Inactivating mutations in the copper transporterAtp7bresult in Wilson’s disease. TheAtp7b−/−mouse develops hallmarks of Wilson’s disease. The activity of several nuclear receptors decreased inAtp7b−/−mice, and nuclear receptors are critical for maintaining metabolic homeostasis. Therefore, we anticipated thatAtp7b−/−mice would exhibit altered progression of diet-induced obesity, fatty liver, and insulin resistance. Following 10 wk on a chow or Western-type diet (40% kcal fat), parameters of glucose and lipid homeostasis were measured. Hepatic metabolites were measured by liquid chromatography–mass spectrometry and correlated with transcriptomic data.Atp7b−/−mice fed a chow diet presented with blunted body-weight gain over time, had lower fat mass, and were more glucose tolerant than wild type (WT) littermate controls. On the Western diet,Atp7b−/−mice exhibited reduced body weight, adiposity, and hepatic steatosis compared with WT controls.Atp7b−/−mice fed either diet were more insulin sensitive than WT controls; however, fastedAtp7b−/−mice exhibited hypoglycemia after administration of insulin due to an impaired glucose counterregulatory response, as evidenced by reduced hepatic glucose production. Coupling gene expression with metabolomic analyses, we observed striking changes in hepatic metabolic profiles inAtp7b−/−mice, including increases in glycolytic intermediates and components of the tricarboxylic acid cycle. In addition, the active phosphorylated form of AMP kinase was significantly increased inAtp7b−/−mice relative to WT controls. Alterations in hepatic metabolic profiles and nuclear receptor signaling were associated with improved glucose tolerance and insulin sensitivity as well as with impaired fasting glucose production inAtp7b−/−mice.
Background: Wilson disease (WD) is an autosomal recessive disorder that results in excessive hepatic copper, causing hepatic steatosis, inflammation, fibrosis, cirrhosis, and liver failure. Previous studies have revealed dysregulation of many farnesoid X receptor (FXR) metabolic target genes in WD, including the bile salt exporter pump, the major determinant of bile flow. Methods: We tested the hypothesis that the FXR-cistrome is decreased in Atp7b
−/
−
mice in accord with dysregulated bile acid homeostasis. Results: FXR binding within Atp7b
−/
−
mouse livers displayed surprising complexity: FXR binding was increased in distal intergenic regions but decreased in promoter regions in Atp7b
−/
−
versus wild-type mice. Decreased FXR occupancy in Atp7b
−/
−
versus wild-type mice was observed in hepatocyte metabolic and bile acid homeostasis pathways, while enrichment of FXR binding was observed in pathways associated with cellular damage outside of hepatocytes. Indeed, disparate FXR occupancy was identified in parenchymal and non-parenchymal marker genes in a manner that suggests decreased FXR activity in parenchymal cells, as expected, and increased FXR activity in non-parenchymal cells. Consistent with altered FXR function, serum and liver bile acid concentrations were higher in Atp7b
−/
−
mice than in wild-type mice. Comparison of bile acid profiles in the serum of WD patients with “liver,” “neurological,” or “mixed” disease versus healthy controls also revealed increases in specific bile acids in WD-liver versus healthy controls. Conclusions: We identified novel FXR-occupancy across the genome that varied in parenchymal and non-parenchymal cells, demonstrating complex FXR regulation of metabolic and hepatocellular stress pathways in Atp7b
−/
−
mice. Dynamic changes in FXR activity support our novel finding of altered bile acid metabolism in Atp7b
−/
−
mice and WD patients.
1 June 2025 in American Journal of Physiology-Endocrinology and Metabolism
Hepatic bile acid signaling plays a crucial role in coordinating systemic metabolism between the liver and other peripheral tissues. Our report demonstrates that, under bile acid-enriched conditions, activation of nuclear receptors CAR and PXR stimulate the expression of several putative hepatokines, including the orosomucoid gene family, which may exert regulatory effects in the liver and adipose tissue against metabolic disorders.
4-Methylumbelliferone (4-MU) is the active component of hymecromone, a choleretic and antispasmodic drug with an excellent safety profile. In rodent studies, high doses of 4-MU are also used to inhibit the production of hyaluronan (HA), a biomarker of liver fibrosis. Further, 4-MU shows excellent efficacy in inhibiting liver fibrosis of different etiologies in animal studies, eliciting interest in its repurposing for this condition. However, 4-MU's mechanism of action, and whether it inhibits liver fibrosis by impeding HA synthesis remains unclear. Using several transgenic mouse models with HA overproduction or degradation in different types of liver cells, we found that both directions of perturbation reduced liver fibrosis levels. In addition, degrading HA via hyaluronidase PH20 overexpression impaired liver function, manifested by increased serum aminotransferase (ALT) activity levels. These findings challenge both the role of HA modulation in 4-MU's action and the strategy of targeting HA to treat liver fibrosis. Additional mouse models also excluded the possibility that 4-MU modulates intestinal farnesoid X receptor (FXR) to inhibit liver fibrosis. Ablation of gut microbiota partially abolishes 4-MU's anti-liver fibrosis effect. However, the anti-liver fibrosis effect of 4-MU was lost in the lower-dose group. Based on these findings, we argue that the lack of efficacy of 4-MU at a translatable dose and the lack of a precise mechanism that allows improvement of 4-MU's efficacy make 4-MU impractical for being repurposed as an anti-liver fibrosis treatment.
15 February 2023 in Molecular and Cellular Endocrinology